Norton Rose Fulbright (Sydney)

Belinda Harvey

Norton Rose Fulbright (Sydney)
Competition and Regulatory Partner

Belinda is a competition/anti-trust and regulatory lawyer based in Sydney. Belinda advises Australian and international corporate clients, utilities, and regulators on all aspects of competition law and the regulation of essential services, including energy, rail, ports and other infrastructure. Belinda has extensive experience in advising on and obtaining clearance for domestic and cross-border mergers and acquisitions, with a particular focus on multi-jurisdictional matters. Her merger clearance experience is well recognised in the Australian legal market. Belinda also advises on the structuring of joint ventures and other collaborative arrangements within the bounds of competition law, anti-competitive conduct and matters of compliance. She has a depth of experience in advising on the economic regulation of utilities, including the electricity, gas, and transport sectors under various Australian regulation, in addition to the access regime under State-based and national competition laws. Belinda is a dedicated competition/anti-trust lawyer with over 10 years’ experience. Prior to joining private practice in 2008, Belinda was a lawyer with the Australian Competition and Consumer Commission (ACCC) advising on mergers and acquisitions, exclusive dealing authorisations, and other competition law litigation. She also worked as an investigator in the enforcement division and as a project officer in the telecommunications group of the ACCC, and in the gas division of the Australian Energy Regulator.


Linked authors

Norton Rose Fulbright (Toronto)
Norton Rose Fulbright (New York)
Norton Rose Fulbright (Brussels)
Norton Rose Fulbright (Paris)
Norton Rose Fulbright (Brussels)


27 Bulletin

Helen Macpherson, Belinda Harvey The Australian Competition Authority publishes draft guidelines on the application of competition laws to IP rights following the removal of the exception with particular significance for the pharmaceutical and life sciences sectors


This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. Introduction Conditions attached to the licensing or assignment of intellectual property (IP) have benefited from an exception to certain provisions of the (...)

Send a message